CoChat

Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

Open access
Mekenkamp, Leonie JM, Tol, Jolien, Dijkstra, Jeroen R, de Krijger, Inge, Vink-Börger, M Elisa, van Vliet, Shannon, Teerenstra, Steven, Kamping, Eveline, Verwiel, Eugène, Koopman, Miriam, Meijer, Gerrit A, van Krieken, J Han JM, Kuiper, Roland, Punt, Cornelis JA, Nagtegaal, Iris D · 2012 · BMC Cancer
Cited by 66

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further improve the selection of patients for this treatment. We assessed the influence of modification of KRAS by gene copy number aberration (CNA) and microRNAs (miRNAs) in correlation to clinical outcome in mCRC patients treated with cetuximab in combination with chemotherapy and bevacizumab. Methods: Formalin-fixed paraffin-embedded primary tumour tissue was used from 34 mCRC patients in a phase III trial, who were selected based upon their good (n = 17) or poor (n = 17) progression-free survival (PFS) upon treatment with cetuximab in combination with capecitabine, oxaliplatin, and bevacizumab. Gene copy number at the KRAS locus was assessed using high resolution genome-wide array CGH and the expression levels of 17 miRNAs targeting KRAS were determined by real-time PCR. Results: Copy number loss of the KRAS locus was observed in the tumour of 5 patients who were all good responders including patients with a KRAS mutation. Copy number gains in two wild-type KRAS tumours were associated with a poor PFS. In KRAS mutated tumours increased miR-200b and decreased miR-143 expression were associated with a good PFS. In wild-type KRAS patients, miRNA expression did not correlate with PFS in a multivariate model. Conclusions: Our results indicate that the assessment of KRAS CNA and miRNAs targeting KRAS might further optimize the selection of mCRC eligible for anti-EGFR therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2407-12-292

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 66

Metadata

Authors
Mekenkamp, L. J., Tol, J., Dijkstra, J. R., de Krijger, I., Vink-Börger, M. E., van Vliet, S., Teerenstra, S., Kamping, E., Verwiel, E., Koopman, M., Meijer, G. A., van Krieken, J. H. J., Kuiper, R., Punt, C. J., & Nagtegaal, I. D.
Venue
BMC Cancer
Published
2012-07-17
Volume
12
Issue
1
Pages
292-292
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2117496975
Cited by
66
References
13
FWCI
3.83
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. https://app.cochat.ai/papers/10.1186/1471-2407-12-292
The paper
Mekenkamp, L. J., Tol, J., Dijkstra, J. R., de Krijger, I., Vink-Börger, M. E., van Vliet, S., Teerenstra, S., Kamping, E., Verwiel, E., Koopman, M., Meijer, G. A., van Krieken, J. H. J., Kuiper, R., Punt, C. J., & Nagtegaal, I. D. (2012). Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer. https://doi.org/10.1186/1471-2407-12-292

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.